References
- Crowley, J. and Ankerst, D.P. (2005). Handbook of Statistics in Clinical Oncology. Boca Raton: Chapman & Hall/CRC.
- FDA. (2010). “Draft Guidance for Industry: Non-Inferiority Clinical Trials.” Available at: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM202140.pdf
- Gardner, M.J. and Altman, D.G. (1986). Confidence intervals rather than P values: estimation rather than hypothesis testing. British Medical Journal 292:746–750.
- Hung, H.M., Wang, S.J. and O’Neill, R. (2005). A regulatory Perspective on Choice of Margin and Statistical Inference Issue in Non-inferiority Trials. Biometrical Journal 1:28–36.
- ICH E-8 (1997). “General Considerations for Clinical Trials.” Available at: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073132.pdf
- ICH E-9 (1998). “Guidance for Industry: E9 Statistical Principles for Clinical Trials.” Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073137.pdf
- ICH E-10 (2000). “Guidance for Industry: Choice of Control Group and Related Design and Conduct Issues in Clinical Trials” Available at: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073139
- Klein, J.P., and Monschberger, M.L. (2003). Survival Analysis Techniques for Censored and Truncated Data. New York: Springer
- Kleinbaum, D.G., Klein, M., and Pryor, E.R. (2010). Logistic Regression ( 3rd ed.). New York: Springer
- Lachin, J.M. (1981). Introduction to sample size determination and power analysis for clinical trials. Controlled Clinical Trials 2:93–113
- Scagliotti, G.V., Parikh, P., von Pawel, J. Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., Lee, J.S., Mellemgaard, A., Park, K., Patil, S., Rolski, J., Goksel, T., de Marinis, F., Simms, L., Sugarman, K.P., Gandara, D. (2006). Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advance-stage non-small-cell lung cancer. Journal of Clinical Oncology 26:3543–3551.
- Qu, Y., Liu, R., Dmitrienko, A., and Offen, W. (2011). A New classification approach for comparing two active treatments when there is no prior projection on which one is better. Statistics in Medicine, 30:3488–3495.
- Vogel, V.G., Costantino, J.P., Wickerham, D.L., Cronin, W.M., Cecchini, R.S., Atkins, J.N., Bevers, T.B., Fehrenbacher, L., Pajon, E.R. Jr, Wade, J.L. 3rd, Robidoux, A., Margolese, R.G., James, J., Lippman, S.M., Runowicz, C.D., Ganz, P.A., Reis, S.E., McCaskill-Stevens, W., Ford, L.G., Jordan, V.C., Wolmark, N.; and National Surgical Adjuvant Breast and Bowel Project (NSABP). (2006). Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. Journal of the American Medical Association 295:2727–2741.